Profile | GDS2987 / Hs.127528-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 10.6 | 36 |
GSM215244 | HMVEC_vehicle_rep2 | ||
GSM215253 | HMVEC_vehicle_rep3 | 3.5 | 12 |
GSM215254 | HMVEC_atorvastatin_rep1 | ||
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 11.4 | 23 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 35.8 | 50 |
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | 32.3 | 48 |
GSM215297 | PASMC_vehicle_rep1 | ||
GSM215298 | PASMC_vehicle_rep2 | ||
GSM215310 | PASMC_vehicle_rep3 | 47 | 59 |
GSM215311 | PASMC_atorvastatin_rep1 | 5.8 | 11 |
GSM215312 | PASMC_atorvastatin_rep2 | 2.3 | 4 |
GSM215313 | PASMC_atorvastatin_rep3 | 17.2 | 26 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 10.1 | 17 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 3.7 | 7 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 4 | 7 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | ||
GSM215329 | PASMC_SLx2119_rep3 | ||
GSM215330 | Fibroblasts_vehicle_rep1 | 8.1 | 20 |
GSM215331 | Fibroblasts_vehicle_rep2 | 11.6 | 32 |
GSM215332 | Fibroblasts_vehicle_rep3 | ||
GSM215333 | Fibroblasts_atorvastatin_rep1 | ||
GSM215334 | Fibroblasts_atorvastatin_rep2 | 17.7 | 44 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 11.2 | 28 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | ||
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | ||
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 1.1 | 3 |
GSM215339 | Fibroblasts_SLx2119_rep1 | ||
GSM215340 | Fibroblasts_SLx2119_rep2 | 8.7 | 24 |
GSM215341 | Fibroblasts_SLx2119_rep3 |